{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:16:29Z","timestamp":1782015389915,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1124\/jpet.118.255620","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T20:55:15Z","timestamp":1557780915000},"page":"127-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist\/\u03b22-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile"],"prefix":"10.1016","volume":"370","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-5591","authenticated-orcid":false,"given":"M\u00f2nica","family":"Aparici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Carcasona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Otal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Cortijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Vilella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"De Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Doe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadeu","family":"Gavald\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Miralpeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.118.255620_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2017.07.003","article-title":"Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist\/\u03b22-adrenoceptor agonist (MABA) molecule","volume":"46","author":"Aparici","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/jpet.118.255620_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2015.11.053","article-title":"In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting \u03b22-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol","volume":"770","author":"Aparici","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.255620_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.112.193284","article-title":"Pharmacological characterization of abediterol, a novel inhaled \u03b2(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models","volume":"342","author":"Aparici","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.255620_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1513\/pats.200409-045MS","article-title":"Distribution of receptor targets in the lung","volume":"1","author":"Barnes","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1124\/jpet.118.255620_bib5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0024-3205(95)00020-7","article-title":"Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease","volume":"56","author":"Barnes","year":"1995","journal-title":"Life Sci"},{"key":"10.1124\/jpet.118.255620_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.pupt.2013.03.015","article-title":"Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD","volume":"26","author":"Bateman","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/jpet.118.255620_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/pats.200504-043SR","article-title":"Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease","volume":"2","author":"Belmonte","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1124\/jpet.118.255620_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/resp.13285","article-title":"Year in review 2017: chronic obstructive pulmonary disease and asthma","volume":"23","author":"Benton","year":"2018","journal-title":"Respirology"},{"key":"10.1124\/jpet.118.255620_bib9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0031-6997(24)01425-X","article-title":"Adrenergic and muscarinic receptors in the human heart","volume":"51","author":"Brodde","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.118.255620_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2013.01.054","article-title":"A role for M(2) and M(3) muscarinic receptors in the contraction of rat and human small airways","volume":"702","author":"Brown","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.255620_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2015.05.020","article-title":"Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy","volume":"761","author":"Calzetta","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.255620_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2018.03.011","article-title":"Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy","volume":"40","author":"Calzetta","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/jpet.118.255620_bib13","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","article-title":"A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD","volume":"149","author":"Calzetta","year":"2016","journal-title":"Chest"},{"key":"10.1124\/jpet.118.255620_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/jpet.111.179259","article-title":"Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol","volume":"337","author":"Casarosa","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.255620_bib15","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1183\/09031936.00067013","article-title":"The MABA approach: a new option to improve bronchodilator therapy","volume":"42","author":"Cazzola","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.118.255620_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.118.255620_bib17","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.chest.2018.07.005","article-title":"Pharmacological therapy of COPD: reasons for optimism","volume":"154","author":"Celli","year":"2018","journal-title":"Chest"},{"key":"10.1124\/jpet.118.255620_bib18","first-page":"785","article-title":"Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA","volume":"11","author":"Cohen","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1124\/jpet.118.255620_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2174\/138920012800166571","article-title":"Optimisation of DMPK by the inhaled route: challenges and approaches","volume":"13","author":"Cooper","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1124\/jpet.118.255620_bib20","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.118.255620_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/13543784.2014.876409","article-title":"Considerations for new dual-acting bronchodilator treatments for chronic obstructive pulmonary disease","volume":"23","author":"de Miguel-D\u00edez","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.118.255620_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0024-3205(93)90312-Q","article-title":"Ba 679 BR, a novel long-acting anticholinergic bronchodilator","volume":"52","author":"Disse","year":"1993","journal-title":"Life Sci"},{"key":"10.1124\/jpet.118.255620_bib23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1124\/jpet.109.151639","article-title":"Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile","volume":"331","author":"Gavald\u00e0","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.255620_bib24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pupt.2014.05.005","article-title":"The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide","volume":"28","author":"Gavald\u00e0","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/jpet.118.255620_bib25","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1183\/09031936.06.00112605","article-title":"Beyond the dogma: novel beta2-adrenoceptor signalling in the airways","volume":"27","author":"Giembycz","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.118.255620_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/jpet.114.216861","article-title":"Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and \u03b22-adrenoceptor agonist properties","volume":"351","author":"Hegde","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.255620_bib27","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1021\/jm501915g","volume":"58","author":"Hughes","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.118.255620_bib28","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4155\/fmc.11.106","article-title":"Dual-pharmacology muscarinic antagonist and \u03b22 agonist molecules for the treatment of chronic obstructive pulmonary disease","volume":"3","author":"Hughes","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1124\/jpet.118.255620_bib29","first-page":"PA1811","article-title":"A randomized placebo controlled trial of AZD8871, a novel dual acting bronchodilator in asthmatics","volume":"50","author":"Jimenez","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.118.255620_bib30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.255620_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40264-016-0402-4","article-title":"Safety considerations with dual bronchodilator therapy in COPD: an update","volume":"39","author":"Matera","year":"2016","journal-title":"Drug Saf"},{"key":"10.1124\/jpet.118.255620_bib32","first-page":"4863","article-title":"In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351)","volume":"44","author":"Miralpeix","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.118.255620_bib33","first-page":"3","article-title":"Regulation of adrenoceptors and muscarinic receptors in the heart","volume":"22","author":"Myslivecek","year":"2003","journal-title":"Gen Physiol Biophys"},{"key":"10.1124\/jpet.118.255620_bib34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/2049-6958-9-50","article-title":"COPD: maximization of bronchodilation","volume":"9","author":"Nardini","year":"2014","journal-title":"Multidiscip Respir Med"},{"key":"10.1124\/jpet.118.255620_bib35","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/13543776.2012.718761","article-title":"Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115?","volume":"22","author":"Norman","year":"2012","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/jpet.118.255620_bib36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.pupt.2013.03.009","article-title":"Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD","volume":"26","author":"Norris","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/jpet.118.255620_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40268-014-0060-x","article-title":"Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials","volume":"14","author":"Norris","year":"2014","journal-title":"Drugs R D"},{"key":"10.1124\/jpet.118.255620_bib38","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1152\/japplphysiol.01546.2005","article-title":"Muscarinic receptors and salivary secretion","volume":"100","author":"Proctor","year":"2006","journal-title":"J Appl Physiol (1985)"},{"key":"10.1124\/jpet.118.255620_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1513\/pats.200504-038SR","article-title":"Beta2-agonist and anticholinergic drugs in the treatment of lung disease","volume":"2","author":"Proskocil","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1124\/jpet.118.255620_bib40","first-page":"OA1656","article-title":"Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients","volume":"52","author":"Psallidas","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.118.255620_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2017.11.043","article-title":"Abediterol (LAS100977), an inhaled long-acting \u03b22-adrenoceptor agonist, has a fast association rate and long residence time at receptor","volume":"819","author":"Ramos","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.255620_bib42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.112.202051","article-title":"Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases","volume":"345","author":"Salmon","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.255620_bib43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/2049-6958-9-60","article-title":"COPD: adherence to therapy","volume":"9","author":"Sanduzzi","year":"2014","journal-title":"Multidiscip Respir Med"},{"key":"10.1124\/jpet.118.255620_bib44","doi-asserted-by":"crossref","first-page":"L1125","DOI":"10.1152\/ajplung.00084.2002","article-title":"Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus","volume":"283","author":"Sarria","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1124\/jpet.118.255620_bib45","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1067\/mai.2002.129966","article-title":"Adverse effects of beta-agonists","volume":"110","author":"Sears","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1124\/jpet.118.255620_bib46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bcp.12545","article-title":"New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives","volume":"79","author":"Singh","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 61","key":"10.1124\/jpet.118.255620_bib47","first-page":"PA1798","article-title":"A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients","volume":"50","author":"Singh","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.118.255620_bib48","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/jpet.112.194456","article-title":"The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium","volume":"343","author":"Sykes","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.255620_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1465-9921-14-49","article-title":"Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease","volume":"14","author":"Tashkin","year":"2013","journal-title":"Respir Res"},{"key":"10.1124\/jpet.118.255620_bib50","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2147\/COPD.S138554","article-title":"When is dual bronchodilation indicated in COPD?","volume":"12","author":"Thomas","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1124\/jpet.118.255620_bib51","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.00165712","article-title":"A new class of bronchodilator improves lung function in COPD: a trial with GSK961081","volume":"42","author":"Wielders","year":"2013","journal-title":"Eur Respir J"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524259139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524259139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.118.255620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:57:51Z","timestamp":1739980671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524259139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0022356524259139"],"URL":"https:\/\/doi.org\/10.1124\/jpet.118.255620","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist\/\u03b22-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.118.255620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}